Revvity RVTY Life Sciences — Payments to Acquire Property, Plant, and Equipment
Discontinued — last reported Q4 '23
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Revvity in its filing.
Tagged under the XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.
The official record: Revvity’s 10-K, filed February 27, 2024, on SEC EDGAR. View the filing →
Ask your AI about Revvity's life sciences — payments to acquire property, plant, and equipment.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Revvity's life sciences — payments to acquire property, plant, and equipment?
- Revvity (RVTY) reported life sciences — payments to acquire property, plant, and equipment of $8.83M in Q4 2023.
- How has Revvity's life sciences — payments to acquire property, plant, and equipment changed year-over-year?
- Revvity's life sciences — payments to acquire property, plant, and equipment decreased by 14.9% year-over-year, from $10.38M to $8.83M.
- What is the long-term trend for Revvity's life sciences — payments to acquire property, plant, and equipment?
- Over 2 years (2021 to 2023), Revvity's life sciences — payments to acquire property, plant, and equipment has grown at a 12.7% compound annual growth rate (CAGR), from $27.82M to $35.34M.
- What does life sciences — payments to acquire property, plant, and equipment mean?
- Cash spent by the Life Sciences segment to buy or build physical assets.
- How do you interpret life sciences — payments to acquire property, plant, and equipment?
- Higher spending indicates investment in future capacity or technology upgrades, while lower spending may indicate a focus on cash preservation.
- How does life sciences — payments to acquire property, plant, and equipment compare across companies?
- Standard capital expenditure (CapEx) metric used to assess investment intensity across all sectors.